Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Dementia and Cognitive Improvement

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 0 · 0%Moderate 2 · 50%High 1 · 25%

Rivastigmine vs placebo

Adverse events (all adverse events) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments

It is very uncertain whether rivastigmine changes adverse events (all adverse events) at 24 to 26 weeks compared with placebo (very low certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 3.21 [0.36, 28.88]
3 studies · 831 participants
Very low

Galantamine vs placebo

Adverse events (all adverse events) at 26 weeks · vascular dementia and other vascular cognitive impairments

Galantamine probably leads to higher adverse events (all adverse events) at 26 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.57 [1.02, 2.43]
2 studies · 1378 participants
Moderate

Donepezil 10 mg/day vs placebo

Adverse events (all adverse events) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.95 [1.2, 3.15]
2 studies · 813 participants
High

Donepezil 5 mg vs placebo

Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.22 [0.94, 1.58]
3 studies · 1772 participants
Moderate